SecBot SecBot
6-K ·Filed Apr 29, 2026

RDY

DR REDDYS LABORATORIES LTD
BULLISH
Impact 6/10
Horizonweeks Processed6mo ago SEC0001575872-26-000265
Notable filing: 6-K
Actionable Insight ▲ Bullish

Monitor launch timeline and initial market share in Canada. The approval positions Dr. Reddy's to capture early generic GLP-1 demand, but pricing and competition dynamics will determine actual financial impact. Watch for updates on U.S. semaglutide approval status.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$13.73
T+0 close · Apr 29, 2026 · via day close
Latest settled
−14.13%
T+60 · $11.79
Vs SPY
−18.24%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 29 $13.73entry
  2. T+1 · 7mo ago −0.66%α −1.68% · $13.64
  3. T+5 · 7mo ago −1.97%α −5.08% · $13.46
  4. T+20 · 6mo ago −1.53%α −7.58% · $13.52
  5. T+60 · 4mo ago −14.13%α −18.24% · $11.79

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Dr. Reddy's received Health Canada approval for its generic Semaglutide Injection, the first generic semaglutide authorized in Canada. This expands the company's GLP-1 portfolio and strengthens its position in the global diabetes market, though no financial terms were disclosed.

Key Facts

  • First generic semaglutide approved by Health Canada for type 2 diabetes
  • Approval covers 2 mg/pen and 4 mg/pen strengths
  • API produced in-house; finished product by OneSource Specialty Pharma
  • Launch preparations are underway
  • Canada is the second-largest market for semaglutide globally (IQVIA)

Financial Impact

Undisclosed; potential for material revenue contribution given Canada's large semaglutide market and first-to-market advantage

revenueeps

Risk Factors

  • Competition from other generic entrants
  • Pricing pressure from payers and branded discounts
  • Manufacturing or supply constraints
  • Regulatory delays in other markets

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
51% bullish (45 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001575872-26-000265
Document: 0001575872-26-000265-index.html0001575872-26-000265
Document: 0001575872-26-000265.txt0001575872-26-000265

Track record

73 reports on RDY

Performance horizon

7 of 11 bullish or bearish reports moved the stock their way by T+5. Best: +23.28% at T+20 after the Jun 26, 2026 report. 7 of 11 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Bullish 4/10 Entry $14.85 Now $14.70 −1.01% settles Nov 23
  2. Nov 10, 20266d ago 6-K Neutral 2/10 Entry $14.86 Now $14.70 −1.08% settles Nov 17
  3. Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $15.05 to $14.70 Now $14.70 −2.33% ▼ −2.33% −0.63% vs SPY
  4. Nov 5, 202611d ago 6-K Neutral 4/10 Entry $14.53 to $14.73 Now $14.70 +1.17% ▲ +1.38% −1.91% vs SPY
  5. Nov 4, 202612d ago 6-K Neutral 2/10 Entry $14.77 to $14.84 Now $14.70 −0.47% ▲ +0.47% +1.39% vs SPY
  6. Nov 2, 202614d ago 144 Bearish 5/10 Entry $14.13 to $15.05 Now $14.70 −4.03% ▼ −6.51% −6.43% vs SPY
  7. Oct 29, 202618d ago 6-K Neutral 2/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
  8. Oct 28, 202619d ago 6-K Neutral 3/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
  9. Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
  10. Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
Showing 10 of 73

US Market Status

Market Closed · Opens in 5h 7m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 29, 2026